New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Upright MRI for Prostate Cancer Screening
Recruiting
This is an investigator initiated study to test the efficacy of an upright MRI (Magnetic Resonance Imaging) for the screening of prostate cancer. The purpose of this study is to compare Upright MRI as a technique to PSA (Prostate Specific Antigen) and current MRI imaging. It will take place at Mount Sinai Hospital, and last for a total of about 5 years. Eligible patients will be determined by the urologist. The target population is men who are at risk for prostate cancer, as determined by the ur... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
10/24/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Prostate Cancer, Elevated PSA, Elevated Prostate Specific Antigen
Sevoflurane Concentrations in Children
Recruiting
The sevoflurane concentrations (as well as vital signs, child's date of birth, type of surgery) will be recorded during the first 10 minutes of anesthesia.
Gender:
ALL
Ages:
Between 2 years and 7 years
Trial Updated:
10/23/2024
Locations: John R. Oishei Children's Hospital, Buffalo, New York
Conditions: Anesthetic, Sevoflurane, Age
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Recruiting
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Melanoma Stage III, Melanoma Stage IV
Exactech Proximal Humerus Fracture Plate System Post Market Clinical Follow-up
Recruiting
The objective of this study is to collect and evaluate long-term clinical outcomes data in order to better understand the safety and performance of the Equinoxe Proximal Humerus Fracture Plates over time. This study will follow subjects for a period of up to 10 years post-surgery.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
10/23/2024
Locations: NYU Grossman School of Medicine, New York, New York
Conditions: Proximal Humeral Fracture, Fracture Dislocation, Non-Union Fracture
Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy
Recruiting
The overall goal of this research is to help develop a new magnetic resonance (MR) method, Quantitative Susceptibility Mapping (QSM), to improve the measurement of liver iron concentrations without the need for a liver biopsy. Measurement of liver iron is important to diagnose and treat patients who have too much iron in their bodies (iron overload). Liver iron measurements by current MRI methods (R2 and R2\*) can be inaccurate because of the effects of fat, fibrosis and other abnormalities. QSM... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
10/23/2024
Locations: Weill Cornell Medical College, New York, New York
Conditions: MRI Scans
Sana Device for Post-Treatment Lyme Disease Syndrome Chronic Pain
Recruiting
This study will investigate the effectiveness of the Sana Pain Reliever (Sana PR) at reducing chronic pain. The Sana PR is a device comprised of one main component (Mask with Earbuds) and two ancillary components (Charger and Headband). The device is worn over the eyes (with earbuds in ears). The device pulses light at a single wavelength but various frequencies throughout a specific firmware algorithm. Through the earbuds, the device also plays different tones in conjunction with the pulses. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York
Conditions: Post-treatment Lyme Disease Syndrome, Chronic Pain
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients with Assist Device
Recruiting
Heart failure is a world epidemic. LVADs are increasingly used as they have demonstrated improved survival rates compared to optimal medical management. Improving outcomes have been seen with the newer LVAD technology, the HeartMate 3 (Abbott, Chicago, IL), however, hemocompatibility related adverse events, including thrombosis and bleeding, are still a major cause of morbidity and mortality. The recent ARIES trial showed that in patients with advanced heart failure treated with a HeartMate3 LVA... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Columbia Irving Medical Center, New York, New York
Conditions: Bleeding, Clot Blood
Lamivudine for Solid Tumors
Recruiting
Single arm, set dose clinical trial of Lamivudine for Relapsed Refractory Solid Tumors. Accrual 6-24 patients, within 2 years, study completion within 3 years at Mount Sinai Health System. Primary Objective: For Phase 1b to determine the safety and tolerability of Lamivudine with continued PD-(L)1 blockade for patients with relapsed/refractory metastatic solid tumors that have progressed on standard PD-(L)1 blockade. For Phase 2, to determine the effect of adding lamivudine to PD-(L)1 blocki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Relapsed/Refractory Solid Tumors
First in Human, Dose Escalation Study of AN4005
Recruiting
Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 + 3 design" will be utilized for dose finding with dose escalation and/or de-escalation as appropriate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Montefiore Einstein Cancer Center, Bronx, New York
Conditions: Advanced Solid Tumor, Advanced Lymphoma
Fibulink Syndesmosis Repair System With Early Full-Weight Bearing
Recruiting
The purpose of the study is to evaluate the ability of the Fibulink Syndesmosis Repair System to maintain reduction of the ankle syndesmosis. Appropriate reduction of the syndesmosis is critical due the changes in tibiotalar contact pressure observed in cadaveric studies.6,7 Malreduction and instability of the distal tibiotalar joint can lead to chronic instability, increased articular damage and ultimately degenerative arthritis.7,8 Medial to lateral translation of distal tibia and fibula of 2... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
10/21/2024
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Ankle Fractures, Bimalleolar Fractures, Syndesmotic Injuries, Bimalleolar Equivalent Fracture, Maisonneuve Fracture, Trimalleolar Fractures, Ankle Dislocation
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/21/2024
Locations: Clinical Site, Albany, New York
Conditions: Parkinson Disease
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
Recruiting
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
Gender:
ALL
Ages:
30 months and below
Trial Updated:
10/21/2024
Locations: Weill Cornell Medicine; Division of Pediatric Neurology, New York, New York
Conditions: Canavan Disease